SAB Biotherapeutics, Inc.

NASDAQ:SABS

Biotechnology

Healthcare
$3.20 -0.53%

-$0.02 today

Market cap
$288.28M
Beta
0.53
P/E (TTM)
3.0
EPS (TTM)
-$0.16
52W Low $1.85High $5.15

Volume 0.89M

Average 0.76M

SABS Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

SAB Biotherapeutics, Inc.NASDAQ: SABS

Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026

Accounts receivables turns negative

Q2 FY2026 accounts receivables was -$897K, compared with $21.39K a year earlier. Trailing-twelve-month accounts receivables was -$2.45M.

Context

  • Accounts receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near -$897K or moves back toward the trailing-twelve-month quarterly average of -$613.02K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$897K+47.5% QoQ
Last fiscal yearDec 2025
-$891.83K+1522.8% YoY
LTMJun 2026
-$2.45M-1190.2% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4294.3%——
1 year+1522.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(891.83K) USD
Year-over-year change
-1522.8%

Accounts Receivables vs competitors

How SABS compares with its peers on the latest reported figures

  • SABS's LTM Jun 2026 accounts receivables of $2.45M is the largest of the 5 companies compared; the peer median is $0.
  • Its year-over-year change of -1190.2% is the lowest of 2, against a peer median of -210.4%.
SABS Competitors Peer median
Accounts Receivables for SABS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SABSSAB Biotherapeutics, Inc.LTM Jun 2026$2.45M -1190.2%——
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026$2.16M -210.4%+121.9%5.8%
QTTBQ32 Bio Inc.LTM Mar 2026$0 ——0.0%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$0 ———
BOLDBoundless Bio, Inc.LTM Mar 2026$0 ———
Peer median (excluding SABS) $0-210.4%+121.9%2.9%

Competitors are the stored peer set for SABS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(17.14M)(18.74M)(42.19M)(34.11M)13.27M
Depreciation & Amortization1.65M3.29M3.75M4.79M3.08M
Deferred Income Tax00000
Stock-Based Compensation2.31M2.67M2.42M2.94M5.21M
Change in Working Capital11.68M(237.58K)2.33M(2.3M)(3.69M)
Accounts Receivables12.56M2.45M5.56M(54.96K)(891.83K)
Inventory00000
Accounts Payables(2.94M)(779.43K)(2.7M)923.32K1.48M
Other Working Capital2.06M(1.91M)(528.64K)(3.17M)(4.28M)
Other Non-Cash Items3.48M(10.45M)8.58M(5.62M)(62.66M)
Operating Cash Flow1.99M(23.46M)(25.12M)(34.29M)(44.78M)
Capital Expenditures(10.94M)(2.17M)(197.15K)(337.26K)(933.15K)
Acquisitions (Net)0000500
Purchases of Investments000(37.45M)(142.04M)
Sales of Investments00025.82M21.26M
Other Investing Activities076.39K44.45K00
Investing Cash Flow(10.94M)(2.09M)(152.7K)(11.96M)(121.71M)
Debt Repayment1.54M(1.19M)(390.45K)(907K)(418.41K)
Common Stock Issued6.75K7.68M020.41K168.73M
Common Stock Repurchased0(5.52M)000
Dividends Paid00000
Other Financing Activities34.34M76.97K59.66M(286.04K)(11.96K)
Financing Cash Flow35.89M1.05M66.77M(1.17M)168.3M
Effect of Forex Changes0018.14K(241.2K)(213.5K)
Net Change in Cash26.93M(24.5M)41.52M(47.67M)1.6M
Free Cash Flow(8.96M)(25.63M)(25.32M)(34.63M)(45.71M)

SAB Biotherapeutics, Inc.

NASDAQ:SABS

Intrinsic Alpha fair value

Locked

Current Price

$3.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.